دورية أكاديمية
Effective dose of remimazolam co-administered with remifentanil to facilitate I-gel insertion without neuromuscular blocking agents: an up-and-down sequential allocation trial
| العنوان: | Effective dose of remimazolam co-administered with remifentanil to facilitate I-gel insertion without neuromuscular blocking agents: an up-and-down sequential allocation trial |
|---|---|
| المؤلفون: | Oh, J, Park, SY, Lee, GY, Park, JH, Joe, HB |
| المساهمون: | 111154, 104200, 104247, Oh, J, Park, SY, Joe, HB |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Adult, Anesthesia, General, Humans, Neuromuscular Blocking Agents, Piperidines, Remifentanil, General anesthesia, I-gel insertion, Remimazolam |
| الوصف: | Background: Remimazolam is a new anesthetic drug developed and is an ultra-short-acting agent with rapid onset and offset. The pharmacology of this drug seems to be ideal for short surgeries eligible for I-gel insertion. Therefore, this study aimed to determine the optimal bolus dose of remimazolam for I-gel insertion when co-administered with remifentanil without neuromuscular blocking agents (NMBAs). Methods: Patients aged 19–65years with American Society of Anesthesiologists physical status I or II scheduled for general anesthesia were enrolled. The first dose of remimazolam was 0.15mg/kg and remifentanil was co-administered at an effect-site concentration (Ce) of 3.0ng/mL. The dose of remimazolam for the following patient was decreased or increased by 0.05mg/kg depending on the success or failure of I-gel insertion in the previous patient. Results: The remimazolam bolus dose required for successful I-gel insertion in 50% of adult patients using modified Dixon’s up-and-down method with remifentanil Ce 3.0ng/mL and no NMBAs was 0.280 ± 0.048mg/kg. Isotonic regression analysis showed that the 50% and 95% effective doses were 0.244 (83% confidence interval [CI] 0.213–0.313) mg/kg and 0.444 (95% CI 0.436–0.448) mg/kg, respectively. The mean time to loss of consciousness (Modified Observer’s Assessment of Alertness/Sedation score < 2) was 52.2s. Three patients (12.0%) showed a reduction in systolic blood pressure of more than 30% from baseline. Conclusions: Selecting the appropriate dose of remimazolam/remifentanil without NMBAs makes it feasible to insert the I-gel. Trial registration: This study protocol was registered at http://cris.nih.go.krTest (KCT0007801, 12th, October, 2022). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1471-2253 |
| العلاقة: | J014712253; http://repository.ajou.ac.kr/handle/201003/25293Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018909Test; BMC anesthesiology, 23(1). : 81-81, 2023 |
| DOI: | 10.1186/s12871-023-02041-z |
| الإتاحة: | https://doi.org/10.1186/s12871-023-02041-zTest http://repository.ajou.ac.kr/handle/201003/25293Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018909Test |
| رقم الانضمام: | edsbas.B39DA05B |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14712253 |
|---|---|
| DOI: | 10.1186/s12871-023-02041-z |